Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios


suck pdf from google scholar
unlimited free pdf from europmc32337790    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32337790  :  Publisher
PDF vom PMID32337790

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics #MMPMID32337790
  • Meziyerh S; Zwart TC; van Etten RW; Janson JA; van Gelder T; Alwayn IPJ; de Fijter JW; Reinders MEJ; Moes DJAR; de Vries APJ
  • Am J Transplant 2020[Jul]; 20 (7): 1896-1901 PMID32337790show ga
  • The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
  • |*Kidney Transplantation[MESH]
  • |*Transplant Recipients[MESH]
  • |Adult[MESH]
  • |Antiviral Agents/administration & dosage/pharmacokinetics[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Chloroquine/administration & dosage/pharmacokinetics[MESH]
  • |Coronavirus Infections/*complications/*therapy[MESH]
  • |Drug Combinations[MESH]
  • |Drug Interactions[MESH]
  • |Everolimus/administration & dosage/*pharmacokinetics[MESH]
  • |Humans[MESH]
  • |Immunocompromised Host[MESH]
  • |Immunosuppressive Agents/administration & dosage/pharmacokinetics[MESH]
  • |Kidney Failure, Chronic/*complications/surgery[MESH]
  • |Lopinavir/administration & dosage/pharmacokinetics[MESH]
  • |Male[MESH]
  • |Netherlands[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/*therapy[MESH]
  • |Radiography, Thoracic[MESH]
  • |Ritonavir/administration & dosage/pharmacokinetics[MESH]
  • |SARS-CoV-2[MESH]
  • |Treatment Outcome[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1896 7.20 2020